Literature DB >> 8150756

A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.

Y C Yee1, C Thornsberry, S D Brown, S K Bouchillon, J K Marler, T Rich.   

Abstract

Using the national surveillance programme of USA hospitals, we selected 162 strains of Streptococcus pneumoniae for sensitivity testing using the NCCLS breakpoints for benzylpenicillin and the oxacillin discs screen test. Included in the group of isolates were 85 relatively penicillin-resistant and 33 penicillin-resistant strains. The activity of cefepime, a new cephalosporin, was compared with other cephalosporins and penicillins as well as some non-beta-lactam antimicrobials. Imipenem was the most active agent but, cefepime, cefotaxime, ceftriaxone and ciprofloxacin were only slightly less active. The least active agents were ceftazidime, cefuroxime, piperacillin/tazobactam and ticarcillin/clavulanate. Cefepime is a potential alternative treatment to penicillin, particularly when penicillin-resistant and relatively penicillin-resistant S. pneumoniae are encountered. The clinical importance of screening for penicillin resistance by the use of the oxacillin disc is emphasized.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8150756     DOI: 10.1093/jac/32.suppl_b.13

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. The Cefepime Study Group.

Authors:  M Zervos; M Nelson
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 2.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 3.  Formulations of antibiotics for children in primary care: effects on compliance and efficacy.

Authors:  Andres Ramgoolam; Russell Steele
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

4.  Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.

Authors:  K S Thomson; S A Chartrand; C C Sanders; S L Block
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 5.  Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; H M Bryson
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.